In solvent-evaporation fabrication of long-acting microparticulate depots, RESOMER L 210 S is selected for high-molecular-weight poly(L-lactide) matrices that remain semi-crystalline and undergo bulk erosion over extended implantation periods. The polymer is dissolved at 5–15% w/v in dichloromethane within a jacketed glass reactor held at 25°C and stirred by an overhead IKA Eurostar 60 at 250–400 rpm. For a peptide or small-molecule active, a primary water-in-oil emulsion is formed with the drug solution added dropwise under an Ultra-Turrax T25 dispersing element operating at 15,000–20,000 rpm for 60–120 s. This primary emulsion is then transferred into an aqueous continuous phase containing 1.0% w/v poly(vinyl alcohol) and 0.1% w/v sodium dodecyl sulfate, maintained at 25°C with a pH of 7.0–7.4. Hardening occurs by controlled solvent evaporation over 6–12 h while stirring at 300–500 rpm. The polymer-to-drug mass ratio is typically 10:1 to 25:1, depending on the required duration of release; higher polymer fractions extend release but also increase residual solvent retention and final particle size polydispersity.

After hardening, microspheres are collected by vacuum filtration through 0.45 µm nylon membranes, washed with water for injection, and lyophilized with a primary drying shelf temperature of -20°C and secondary drying at 20°C for 24–48 h. Particle size distribution is measured by laser diffraction using a Malvern Mastersizer 3000 with a Hydro MV dispersion unit; the volume mean diameter is typically controlled between 20 µm and 80 µm for intramuscular injection, and the span value is kept below 1.5 to avoid Ostwald ripening and dose content heterogeneity. Residual dichloromethane and chloroform are quantified by headspace gas chromatography according to USP <467> and ICH Q3C. The terminal container is a single-dose vial with a sterile dry powder; the reconstitution vehicle is an aqueous suspending medium composed of 0.9% sodium chloride plus 0.5% carboxymethylcellulose sodium and 0.1% polysorbate 20. This application is limited by the high molecular weight of RESOMER L 210 S: the combination of slow bulk erosion and acidic autocatalytic core degradation can extend release lag and delay complete mass loss. If a shorter release interval is required, blending with a lower-viscosity PLGA or PLLA grade is used; published data for this specific grade in blend form with highly water-soluble peptides is limited and must be verified by parallel comparative lots.

Table 1. Residual solvent compliance matrix for L 210 S microsphere manufacturing.

What Limits Injection Molding of Lactide-Based Interference Screws Below 210°C?

Injection molding of bioresorbable interference screws from RESOMER L 210 S is constrained by the narrow window between sufficient melt fluidity and autocatalytic chain scission. The formulation is neat RESOMER L 210 S without plasticizer or comonomer. The resin is first dried in a vacuum oven at 80°C under 0.1 mbar for 8–12 h until moisture content is less than 200 ppm; water above this threshold hydrolyzes ester linkages during plastication. A servo-hydraulic injection molding machine with clamp force between 500 kN and 800 kN and screw diameter of 25 mm is used. Barrel zones are set at 160°C feed, 185°C compression, 195°C metering, and 200°C nozzle. Melt temperature is maintained at 195–205°C, and total residence time is limited to 6–8 min. The mold is hot-oil thermostatted at 30–40°C; higher mold temperatures promote crystallization of the poly(L-lactide) but also increase cycle time and part ejection friction. Injection speed is set at 30–80 mm/s with a hold pressure of 600–900 bar for 5–10 s and a cooling time of 25–35 s. The screw back pressure is held at 20–50 bar to avoid gas bubbles from trace monomer without excessive shear heating. Molecular weight retention after molding is checked by gel permeation chromatography in chloroform with refractive index detection.

The terminal component is a cannulated interference screw for anterior cruciate ligament reconstruction, with a major diameter of 7–10 mm, length of 20–30 mm, and a hexagonal or Torx drive. After molding, the screw is annealed in a nitrogen-purged oven at 100–110°C for 4–6 h to stabilize crystallinity and reduce warpage during gamma sterilization. Sterilization is performed by gamma irradiation at 25–35 kGy, which reduces the molecular weight of PLLA; therefore initial mechanical properties must exceed final specifications by a margin determined under ASTM F2502-17. Biocompatibility is assessed under ISO 10993-5 for cytotoxicity, ISO 10993-10 for irritation and sensitization, and ISO 13781:2017 for bioresorbable implant performance. The melt-processing limitation is unambiguous: at nozzle temperatures above 210°C, discoloration and monomer generation increase sharply, while below 185°C the high-molecular-weight poly(L-lactide) does not fill thin cannulated walls reproducibly. This is the critical processing narrow window for neat RESOMER L 210 S.

Craniomaxillofacial plate forming and low-temperature CNC machining

For craniomaxillofacial plate stock, RESOMER L 210 S is compression molded on a heated hydraulic press with water-cooled platens and a programmable cooling ramp. Dried pellets are spread in a 2–3 mm thick matched-die frame and heated to 190°C under 20 bar contact pressure for 3–5 min, then pressed to 100–120 bar for 8–10 min. The platens are cooled at 10–15°C/min to 110°C before ejection; this controlled cooling reduces warpage and gives a semi-crystalline sheet with reproducible thickness. CNC machining of the plates uses a 5-axis mill with polycrystalline diamond end mills of 2–4 mm diameter, spindle speed 12,000–18,000 rpm, feed 0.05–0.10 mm/tooth, and dry nitrogen gas flooding to keep the cut surface below 60°C. Moisture during storage at 23°C and 50% RH for more than 24 h increases the amorphous phase and can cause ductile-to-brittle transition at machined edges; therefore the sheet is stored in sealed foil with silica gel until immediate machining.

Terminal components include orbital floor reconstruction plates, midface fixation plates, and mandibular trauma plates. Screw holes are tapped for 1.5 mm or 2.0 mm PLLA screws; plate thickness is 0.8–1.5 mm. After machining, parts are cleaned with isopropanol and dried under vacuum at 40°C. Packaging is double-pouch according to ISO 11607-1:2019. Compliance for these craniomaxillofacial devices includes ISO 13485 manufacturing controls, ISO 10993-5 cytotoxicity, ISO 10993-6 implantation testing, and ISO 15814:2010 for in vitro degradation of polylactide-based resorbable bone plates. Because the raw material is neat PLLA, no plasticizer, comonomer, or filler is used; the mechanical properties are therefore dependent on annealing and machining damage. The main operational boundary is that laser cutting induces heat-affected zones and monomer generation in PLLA and is not recommended for L 210 S plate profiles where notch sensitivity under ASTM D638-14 tensile loading cannot be tolerated.

When the grade is dissolved at low solids for spray-coated cardiovascular device matrices, the process constraints shift from melt rheology to solvent volatility and phase separation control. RESOMER L 210 S is dissolved in a chloroform-acetone mixture at 90:10 v/v to a polymer concentration of 2.0% w/v. A therapeutic agent such as sirolimus or everolimus is added at a drug-to-polymer mass ratio of 30:70 w/w; this ratio provides a continuous PLLA matrix while maintaining drug dispersion. Coating is performed with an ultrasonic atomizer operating at 60 kHz, tip flow rate of 0.5–1.0 mL/min, and a nozzle-to-stent distance of 15–25 mm. The stent rotates at 50–150 rpm on a mandrel inside a temperature-controlled coating chamber at 25–35°C and relative humidity below 40%. Humidity above 40% causes rapid evaporative cooling and water condensation, producing surface pores and drug-rich aggregates. The target dry coating thickness is 5–10 µm across the abluminal and luminal surfaces; thickness is measured by confocal laser scanning microscopy and coating uniformity is evaluated under ISO 25539-1:2020 for cardiovascular endovascular devices.

Residual chloroform is controlled to below 60 ppm and acetone to below 5000 ppm by post-coating drying at 45°C under vacuum for 24–48 h, with quantification by headspace GC according to USP <467> and ICH Q3C. Sterilization of the coated stent is typically by ethylene oxide because gamma irradiation at sterilizing doses accelerates PLLA chain scission and shifts drug release; ethylene oxide residuals follow ISO 10993-7. Biocompatibility endpoints are based on ISO 10993-5, ISO 10993-6, and hemocompatibility testing under ISO 10993-4. The terminal product is a drug-eluting coronary stent with a bioresorbable PLLA coating. The critical formulation boundary is that increasing drug load above 50% w/w reduces the PLLA continuous phase strength and produces delamination on balloon expansion, whereas reducing polymer concentration below 1.0% w/v increases coating roughness. Published data for RESOMER L 210 S specifically as a stent coating matrix are limited relative to lower-molecular-weight PLLA and PLGA grades; coating trials with the grade must include molecular weight retention analysis after ultrasonic spraying.

When L 210 S Is Melt-Spun into Oriented Monofilament for Ligament Anchors

Melt-spun PLLA monofilament used in braided suture anchors and ligament fixation textiles requires controlled orientation without filament breakout. The grade is predried to less than 200 ppm moisture and fed to a 16 mm single-screw extruder with L/D 25:1 and a gear pump to damp pressure pulses. Barrel temperatures are 175°C in the feed zone, 185°C in compression, and 190°C at the metering zone; the die temperature is held at 195°C. The melt is extruded through a 1.0 mm spinneret into a water quench bath at 20–25°C and then drawn over two heated godets. The first godet is set at 60°C and the second at 85–95°C; the draw ratio is maintained between 6:1 and 8:1. Below 6:1, tensile strength under ASTM D2256 is insufficient for knot pull tests; above 8:1, filament breakage on production winders exceeds 5 breakages per 10,000 m when run at 80–120 m/min. After drawing, the spun monofilament is annealed in line at 100°C for 1–2 min under controlled tension to reduce thermal shrinkage.

The finished monofilament has a diameter of 0.15–0.30 mm and is braided into suture anchor limbs or woven as scaffold textiles. Knot pull strength is tested according to USP <861> and ASTM D2256; the medical device component is sterilized by ethylene oxide, with residual ethylene oxide and ethylene chlorohydrin controlled under ISO 10993-7. Biocompatibility includes ISO 10993-5 and ISO 10993-6. The main process incompatibility is prolonged hold time in the metering section above 200°C, which degrades molecular weight and produces weak filaments that snap at the first godet. No plasticizer or comonomer is used; therefore the spinning window is narrower than for PLGA copolymers, but the resulting oriented PLLA retains semicrystalline load-bearing capacity for bone-ligament fixation.

Fused deposition scaffold filament produced from medical-grade PLLA.

Neat RESOMER L 210 S can be converted into filament for extrusion-based additive manufacturing of patient-specific bone scaffolds and temporary fixation guides. Pellets are dried to less than 200 ppm moisture and extruded through a 1.75 mm diameter die on a single-screw extruder at 180–200°C. The filament is cooled in a water bath at 25°C, hauled through a laser diameter gauge, and wound with a target diameter of 1.75 mm ±0.05 mm and ovality below 0.03 mm. The spooled filament is then processed in a fused deposition modeling printer with a hardened steel nozzle of 0.4 mm, nozzle temperature 200–220°C, bed temperature 55–65°C, layer height 0.12–0.20 mm, and print speed 20–40 mm/s. The build chamber is maintained below 30% RH to prevent moisture-induced filament popping. The terminal product is a resorbable interbody or craniofacial scaffold with open porosity controlled by the print infill, typically 40–70%.

Compliance for the printed scaffold includes ISO/ASTM 52900:2021 for additive manufacturing terminology and processes, ISO 10993-5, ISO 10993-6, and ASTM F2502-17 for bioresorbable implant testing. Because fused deposition modeling parts are anisotropic, tensile testing is performed using ASTM D638-14 Type V specimens printed in both horizontal and vertical orientations; interlayer adhesion is the weakest mode and is measured by overlap shear according to ASTM D5868-01. The process boundary is nozzle residence time: at 220°C with low print speed and long idle periods, viscosity reduction and char formation can block the 0.4 mm nozzle. Published data for L 210 S as an FDM filament are limited; therefore each lot must be tested for melt flow rate after filament extrusion and again after printing to ensure that molecular weight loss does not exceed the acceptance window established by the device manufacturer.